Light Mode
$4.45 ↑ +0.09 (+2.06%) Trading Up from the previous close of $4.36
-2.58 (-37.18%) / 6M
Momentum, market sentiment, and recent alerts
TSHA reads very good: price sits above one of the two key moving averages, the 12-month move is +8.2%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.